Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 11, 2019 - Issue
Submit an article Journal homepage
92
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient

Marie Fournier1 Health Economics & Value Assessment, Sanofi France, Chilly-Mazarin, France, [email protected]Correspondence[email protected]
,
Chieh-I Chen2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
,
Andreas Kuznik2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
,
Clare Proudfoot3 Sanofi, Guildford, UK
,
Usha G Mallya4 Sanofi, Bridgewater, NJ, USA
&
Kaleb Michaud5 University of Nebraska Medical Center, Omaha, NE, USA;6 The National Databank for Rheumatic Diseases, Wichita, KS, USA
Pages 117-128 | Published online: 05 Feb 2019

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Sajith Kumar & Bhavani Shankara Bagepally. (2023) Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies. Expert Review of Pharmacoeconomics & Outcomes Research 0:0, pages 1-14.
Read now
Matthew Sussman, Charles Tao, Pankaj Patel, Namita Tundia, Jerry Clewell & Joseph Menzin. (2020) Cost-utility analyses of targeted immunomodulators in rheumatoid arthritis: systematic review. Journal of Medical Economics 23:6, pages 610-623.
Read now

Articles from other publishers (5)

S. Sajith Kumar, Madhumitha Haridoss, Krishnamurthy Venkataraman & Bhavani Shankara Bagepally. (2022) Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies. Frontiers in Pharmacology 13.
Crossref
D. E. Karateev & E. L. Luchikhina. (2019) New possibilities of drug therapy for rheumatoid arthritis: focus at sarilumab. Almanac of Clinical Medicine 47:5, pages 461-469.
Crossref
Noemi MuszbekClare Proudfoot, Marie FournierChieh-I ChenAndreas KuznikZsofia KissPeter Gal & Kaleb Michaud. (2019) Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Journal of Managed Care & Specialty Pharmacy 25:11, pages 1268-1280.
Crossref
Shirly Frizinsky, Soad Haj-Yahia, Diti Machnes Maayan, Yulia Lifshitz, Ramit Maoz-Segal, Irean Offengenden, Mona Kidon & Nancy Agmon-Levin. (2019) The innate immune perspective of autoimmune and autoinflammatory conditions. Rheumatology 58:Supplement_6, pages vi1-vi8.
Crossref
. (2019) Sarilumab cost effective for active rheumatoid arthritis. PharmacoEconomics & Outcomes News 822:1, pages 29-29.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.